Business
Currency:USD
2024/Q1
Stock NameRevenueRatio
Xywav315.3M34.96%
Epidiolex/Epidyolex198.72M22.03%
Rylaze/Enrylaze102.75M11.39%
Zepzelca75.1M8.33%
Xyrem64.23M7.12%
High-sodium oxybate AG royalty revenue49.95M5.54%
Defitelio/defibrotide47.68M5.29%
Vyxeos32.02M3.55%
Other royalty and contract revenues9.93M1.10%
Other6.31M0.70%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
United States3.49B91.02%
Europe269.24M7.02%
All other74.98M1.96%
